The global Next Generation Sequencing market size was valued at USD 8.49 billion in 2018 and is expected to register a CAGR of 12.78% over the forecast period. Introduction of advanced and rapid sequencing technologies for clinical processes is expected to drive the market. The advancement in the bioinformatics field also drive the adoption of NGS platforms in diagnosis and analysis of rare diseases, identifying therapeutic targets, and for prenatal testing. Over the forecast period, NGS methodologies are expected to witness high demandin clinical diagnosis, genomics research, and in the precision treatment of varied diseases.
Moreover, due to rapid development of companion diagnostics in delivering advanced genomic and personalized medicine, is poised to fuel the market growth in the near future. Advent of targeted therapies in oncology and other fields has significantly transformed the companion diagnostics. The NGS techniques are likely to help expand the companion diagnostics vertical, as NGS panels are capable of measuring several biomarkers in one test. Consequently, this makes the NGS method as ideal targeted therapies in delivering precision medicine.
Significant reduction in the cost of genetic sequencing from USD 95.26 million per genome in 2001 to USD 108.1 thousand in 2009 and USD 1,000 - 1200 in 2017 will boost the market. The prices for installation of sequencing platforms is also decreasing significantly. This is also expected to have a positive impact on the demand for NGS techniques. Development of novel products and services by prominent companies is also expected to propel market growth. For instance, in August 2018, Illumina received approval for MiSeq Dx Sequencing System from the China National Drug Administration.
Companies are also focusing on the introduction of economical sequencing devices for routine medical checkups as well as increasing their installation base by providing the NGS services in different countries. For instance, in June 2018, Oxford Gene Technology expanded its NGS Custom Cancer Panel, SureSeq myPanel, which enabled the researchers to focus on cancer-related genes. Whereas, in April 2018, Agilent Technologies signed an agreement to acquire Lasergen, Inc. to boost next-generation sequencing workflow for clinical applications.
NGS platforms and related products accounted for the majority of the market share in 2018. It comprises sequencing platforms, instruments, and software that are used during the preparation of samples, libraries, and sequencing of those samples. The most widely used NGS-based platforms/products include Illumina’s MiSeq, MiniSeq and NextSeq, Thermo Fisher’s Ion PGM, Ion Proton System, and Ion GeneStudio S5 NGS system and Oxford Nanopore Technologies’ MinION.
On the other hand, the NGS services segment is expected to be a promising segment during the forecast period. Key companies, such as Illumina, Inc.; Roche; and Pacific Biosciences, offer a wide suite of sequencing services on their NGS platforms. These services assist the researchers to better understand genomic sequences, develop personalized medicines, and in the diagnosis of rare and chronic diseases, such as cancer.
Oncology was the key application segment in 2018. With the rapid expansion of NGS capabilities, it is possible to sequence multiple genomes simultaneously and targeted sequencing of several cancer genes, consequently allowing the oncologists to access genetic information present in gene clusters related to tumor cells and cancer.Rapid proliferation in genealogy, paternity testing, and rising health awareness is anticipated to boost growth of consumer genomics over the forecast period. Companies, such as 23andMe, are involved in the provision of the “Personal Genome Service”.
Targeted sequencing & resequencing is marked with higher market penetration rates as it is a rapid and cost-effective technology used for detecting known variants in selected sets of genes. Illumina, Inc. provides targeted resequencing with its gene panel and array finder, whereas Sequel System of Pacific Biosciences of California allows targeted sequencing.
However, Whole Genome Sequencing (WGS) is expected to witness considerable growth in near future. WGS is a newer technology that encompasses genome, microbial resequencing, and de novo genome sequencing. It is mostly applicable in research applications, such as risk assessment studies in antimicrobial resistance genes across the food chain.
In terms of revenue, sequencing was the most important phase of the workflow and consequently accounted for the largest market share in 2018. It is projected to maintain its dominance over the forecast period. Intense industry competition has resulted in the launch of a novel, portable platforms, such as iSeq, MiniSeq, MiSeq, series from Illumina and Ion Proton, PGM, IonS5 system from Thermo Fisher Scientific.
This is likely to support the segment growth. Following a similar trend, data analysis is expected to witness a strong CAGR due to the advent of novel algorithmsoffering quick results. For instance, the presence of analysis tools, such as BaseSpace Suite by Illumina, helps in the management of large volumes of sequencing data.
Academic research was the largest end-use segment in 2018 and is likely to expand further on account of wide usage of NGS methodologies in research and Ph.D. projects, on-site bioinformatics courses, and workshops. Several universities and research centers provide molecular biology courses and NGS applications. For instance, the Wageningen University & Research in the Netherlands offers state-of-the-art NGS facilities and technology for several clinical applications, thus inducing substantial growth in this segment.
The clinical research segment will register the fastets CAGR in the forecasr years as NGS is used in cancer research for the discovery of new cancer-related genes, reviewing tumor heterogeneity, and detection of alterations. Availability of clinical research solutions through market entities for screening and detection purposes also accelerates the vertical progression.
North America was the key regional market in 2018 and will expand further due to simultaneous developments of NGS, precision medicine, and companion diagnostics. As these biotechnology sectors are capital-intensive, high R&D investment in the region complement the inter-related development of these sectors. Moreover, majority of the academic research centers, hospitals, and clinics using NGS products and services are located in U.S.
Strong presence of prominent firms, such as Roche Holding AG, contributes to the introduction of rapid and high throughput sequencing capabilities, thereby boosting the market growth. Asia Pacific is also projected to have a lucrative growth due to significant developments initiated by key companies for technological integration of NGS methodologies. For instance, in January 2018, Illumina, Inc. collaborated withKingMed Diagnostics to utilize Illumina’s NGS technology for oncology and hereditary disease testing.
Key companies in the global market include Illumina Inc.; QIAGEN; F Hoffman-La Roche Ltd.; Thermo Fisher Scientific, Inc.; PierianDx, Inc.; Genomatix GmbH; Eurofins GATC Biotech GmbH; Oxford Nanopore Technologies; DNASTAR, Inc.; BGI; Perkin Elmer, Inc.; and Bio-Rad Laboratories, Inc. Market participants focus on collaborative models and are undergoing geographic expansion strategies majorly in untapped regions. For instance, in April 2018, Illumina collaborated with Bristol-Myers Squibb for the employment of Illumina’s NGS capabilities to develop and commercialize in-vitro diagnostic assays to support Bristol’s oncology portfolio.
Base year for estimation
Actual estimates/Historical data
2014 - 2018
2019 - 2025
Revenue in USD Million and CAGR from 2019 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, Japan, China, Brazil, and South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analysts working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global next generation sequencing market report on the basis of products & services, application, technology, workflow, end use, and region:
Products & Services Outlook (Revenue, USD Million, 2014 - 2025)
Platforms & Related Products
Application Outlook (Revenue, USD Million, 2014 - 2025)
Diagnostics and Screening
Newborn Genetic Screening
Single Gene Analysis
HLA Typing/Immune System Monitoring
Metagenomics, Epidemiology & Drug Development
Agrigenomics & Forensics
Technology Outlook (Revenue, USD Million, 2014 - 2025)
Targeted Sequencing & Resequencing
Workflow Outlook (Revenue, USD Million, 2014 - 2025)
NGS Library Preparation Kits
Semi-automated Library Preparation
Automated Library Preparation
NGS Primary Data Analysis
NGS Secondary Data Analysis
NGS Tertiary Data Analysis
End Use Outlook (Revenue, USD Million, 2014 - 2025)
Hospitals & Clinics
Pharma & Biotech Entities
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."